Zealand Pharma A/S (OTCMKTS:ZLDPF) Lowered to Hold Rating by Barclays

Zealand Pharma A/S (OTCMKTS:ZLDPF) was downgraded by investment analysts at Barclays from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.

Other research analysts have also issued reports about the stock. Zacks Research lowered shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Wolfe Research cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $46.38 on Tuesday. The company’s 50 day moving average is $47.47 and its 200-day moving average is $47.39. Zealand Pharma A/S has a 12-month low of $35.93 and a 12-month high of $83.12. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The firm has a market cap of $3.32 billion, a P/E ratio of 7.69 and a beta of 0.89.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.